oncology

Even during my university days, I would find myself grasping my chest, wheezing after a short 15-minute walk to campus. In terms of fitness, I would consider myself to…
In this episode, we revisit Valeo Pharma (VPH.C) to get an update on their product portfolio, stock price, and financials. Is VPH.C a good long term investment? Tune In!…
Valeo Pharma (VPH.C) is a specialty pharmaceutical company, engages in the acquisition, in-licensing, and commercialization of pharmaceutical products with a primary focus on neurodegenerative diseases, oncology and supportive care, and…
NuCana PLC (NCNA.Q) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Acerlarin® (NUC-1031), which is currently being evaluated in a Phase…
Innate Pharma S.A. (IPHA.Q) announced today that AstraZeneca has presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on…
Leap Therapeutics (LPTX.Q) announced today that it will be presenting initial data from the first-line cohort of the DisTinGuish study at the European Society for Medical Oncology (ESMO) Congress….
Adaptimmune Therapeutics (ADAP.Q) announced today that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogenic…
Trillium Therapeutics (TRIL.V) announced today that the Company has entered into a definitive agreement under which Pfizer Inc. will acquire Trillium.     “We’re delighted to announce Pfizer’s proposed…
iBio Inc. (IBIO.NYSE) announced yesterday that it has added three anti-cancer targets to its pipeline of therapeutic candidates. This development establishes the Company’s new drug discovery capabilities announced just…
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement…